Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 September 2020 | Story Andre Damons | Photo Supplied
Dr Martin Nyaga, Senior Lecturer and Researcher: NGS, will be heading the World Health Organisation Collaborating Centre (WHO CC).

The University of the Free State (UFS) has been designated a World Health Organisation Collaborating Centre (WHO CC), and the university’s Next Generation Sequencing (NGS) Unit, in partnership with the World Health Organisation (WHO), will for the next four years be conducting genome sequencing of pathogenic organisms, including rotavirus strains from the African continent. 

This centre will be part of the Vaccine Preventable Diseases (VPD) Pathogens Genomics Cluster and will run from September 2020 to September 2024. 

Dr Martin Nyaga, Senior Lecturer and Researcher: NGS/Virology, who will be heading the WHO CC, says an institution is designated as a WHO CC by the WHO Director-General and endorsed by the host country’s minister of health to form part of an international collaborative network, carrying out activities in support of the WHO programmess at all levels. A designation as a WHO CC is a time-limited agreement of collaboration between WHO and the designated institution, through which the latter agrees to implement a series of concrete activities, specifically designed for WHO.

A supreme achievement

Says Dr Nyaga: “In my opinion, a WHO CC designation is one of the supreme achievements an institution can be conferred as a recognition for foregoing exceptional collaborative venture with the WHO and showing future potential to assist the WHO with its global programmes and in our case, the WHO Regional Office for Africa region to offer solutions to the WHO VPD Surveillance and pathogens genomics cluster.”

According to Dr Nyaga this designation was awarded to the UFS after the WHO was content with the outcome of a service contract whereby the UFS-NGS unit undertook a pilot rotavirus surveillance project at whole genome level, using two African countries for the pilot, Rwanda and Zambia.

“From the outcomes of the pilot surveillance project between 2017 and 2019, the WHO/AFRO was satisfied with the genomic data that was generated and partially disseminated in scientific databases and journals as a collaborative venture. 

“It was thus proposed to strengthen its existing collaboration with the UFS-NGS Unit, which initiated the application process to designate the UFS-NGS unit as a WHO CC, an initiative that has taken approximately 20 months to finalise through the different phases of the application and approvals for the designation,” explains Dr Nyaga.

The purpose of the WHO CC

The new WHO CC will upon request by the WHO, implement agreed work plans in a timely manner and to the highest possible standards of quality and must comply with the referred terms of reference and conditions. These include: 
• Conducting genome sequencing of pathogenic organisms causing VPD, including rotavirus strains collected as part of the routine VPD surveillance using NGS technology and analysis of the generated datasets using bioinformatics tools.

• Conducting molecular characterisation of specimens collected during outbreaks and public health emergencies as part of the support for monitoring, preparedness and response to VPD disease outbreaks in Africa.

• Provide technical guidance to WHO on strategies to improve laboratory molecular diagnostics, molecular typing and NGS of rotavirus diarrheal strains and other enteropathogens to detect novel and re-emerging strains. 

• Conduct validation of tools and new molecular diagnostics for detection and characterisation of unusual or rare VPD strains to guide studies and development of new vaccines for VPD.

• Organise capacity-building and training workshops on whole genome sequencing of priority VPD pathogenic organisms.

The impact of the WHO CC on the work of the UFS-NGS 

According to Dr Nyaga, the designation brings extra responsibilities to his work and to the activities of the UFS-NGS unit. “Such initiatives are very welcome to enhance the business aspects, research and academic activities of the UFS-NGS unit, as the benefits are quite holistic since the collaboration enhances co-ownership of data and offers opportunities to train postgraduate students and other scientists.

“It also expands the research infrastructure and most importantly contributes to policy for numerous African governments in important decisions such as vaccine implementation activities, from an informed point of view and managing public health needs that require rapid response like outbreaks that may lead to pandemics.” 
• The current WHO CC designations at South African Institutions of higher learning and research can be found at: 

News Archive

Link between champagne bubbles and the UFS?
2012-11-16

Prof. Lodewyk Kock with an example of a front page of the publication FEMS Yeast Research, as adapted by F. Belliard, FEMS Central Office.
Photo: Leatitia Pienaar
15 November 2012

What is the link between the bubbles in champagne and breakthrough research being done at the Mayo Clinic in America? Nano research being done at our university.

Prof. Lodewyk Kock of Biotechnology says a human being consists of millions of minute cells that are invisible to the eye. The nano technology team at the UFS have developed a technique that allows researchers to look into such a cell, as well as other microorganisms. In this way, they can get an idea of what the cell’s “insides” look like.

The UFS team – consisting of Profs. Kock, Hendrik Swart (Physics), Pieter van Wyk (Centre for Microscopy), as well as Dr Chantel Swart (Biotechnology), Dr Carlien Pohl (Biotechnology) and Liza Coetsee (Physics) – were amazed to see that the inside of cells consist of a maze of small tunnels or blisters. Each tunnel is about 100 and more nanometres in diameter – about one ten thousandth of a millimetre – that weaves through the cells in a maze.

It was also found that these tunnels are the “lungs” of the cells. Academics doing research on yeast have had to sit up and take notice of the research being done at the UFS – to the extent that these “lungs” will appear on the front page of the highly acclaimed FEMS Yeast Research for all of 2013.

The Mayo Clinic, in particular, now wants to work with the UFS to study cancer cells in more detail in order to fight this disease, says Prof. Kock. The National Cancer Institute of America has also shown interest. This new nano technology for biology can assist in the study and development of nano medicine that can be used in the treatment of cancer and other life threatening diseases. Nano medicine uses nano metal participles that are up to one billionth of a metre in size.

Prof. Kock says laboratory tests indicate that nano medicine can improve the efficacy of anti-cancer medicine, which makes the treatment less toxic. “According to the Mayo Clinic team, nano particles are considered as a gold cartridge which is being fired directly at a cancer tumour. This is compared to fine shot that spreads through the body and also attacks healthy cells.”

“This accuracy implies that the chemotherapy dose can be lowered with fewer side effects. The Mayo Clinic found that one-tenth of the normal dosage is more effective against pancreas cancer in this way than the full dosage with a linkage to nano particles. According to the clinic, this nano medicine could also delay the spread of cancer,” says Prof. Kock.

The nano particles are used as messengers that convey anti-cancer treatment to cancer cells, where it then selectively kills the cancer cells. The transport and transfer of these medicines with regard to gold nano particles can be traced with the UFS’s nano technology to collect more information, especially where it works on the cell.

“With the new nano technology of the UFS, it is possible to do nano surgery on the cells by slicing the cells in nanometre thin slices while the working of the nano medicine is studied. In this way, it can be established if the nano medicine penetrates the cells or if it is only associated with the tiny tunnels,” says Prof. Kock.

And in champagne the small “lungs” are responsible for the bubbles. The same applies to beer and with this discovery a whole new reach field opens for scientists.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept